The effect of chronic oral opioids on hypothalamus-pituitary-gonadal axis in women, and on bone mineral density (BMD) in men and women is not known. The objective of this cross-sectional study was to determine the effect of long-term oral opioids on gonadal status and BMD in male and female patients with chronic non-cancer pain (CNCP). We included 26 community-dwelling CNCP patients, 12 men and 14 premenopausal women, treated with oral opioids for at least one year. We obtained Visual Analogue Scale for pain score, BMD and plasma LH and FSH in all patients; menstrual history and estradiol in women; free androgen index and total and free testosterone in men. Men were older then women (p < 0.05) and had used opioids for a longer period (7.2 ± 3.8 and 4.1 ± 1.8 years, respectively; p < 0.05), but there was no difference in opioid dose or pain score between sexes. The prevalence of hypogonadism was high in men (75 %), while only 21 % of the women reported oligoor amenorrhea indicating hypogonadism (P < 0.01, between sexes). Osteopenia was found in 50 % of men and 21 % of women (p = NS). We conclude that in CNCP patients receiving chronic opioid therapy there is a much higher prevalence of hypogonadism in men then in women. This needs to be considered clinical practice.

Placental mesenchymal dysplasia (PMD) is a rare placental malformation of as yet undetermined etiology. We report a single center's experience of this diagnosis and present an estimation of the population incidence. Within our institution, all placentae are examined within a pathology department that provides a dedicated perinatal service. In this study, we evaluated the incidence of PMD over a period of 18 years following the description and recognition of PMD as a pathological diagnosis. During the period 1991-2009, only two cases were identified amongst over 95 000 deliveries at our institution. This series of placental examinations is by far the largest in a normal population within which the occurrence of PMD is reported, and the resulting incidence of only 0.02 per 1000 deliveries is some 10 times less than that which has previously been estimated.

A, et al. Evaluation of complications in postpartum women receiving therapeutic anticoagulation. Obstet Gynecol 2020;136. The authors provided this information as a supplement to their article.